Clinical outcome in different cytogenetic groups according to MRD status after consolidation. (A) Overall survival (OS), (B) relapse-free survival (RFS), and (C) cumulative incidence of relapse (CIR) of 143 AML patients stratified according to levels of MRD after consolidation. Those with a level of residual leukemic cells less than 3.5 × 10⁻⁴ are referred to as intermediate K-MRD⁻ or good K-MRD⁻, whereas those with levels more than or equal to 3.5 × 10⁻⁴ are categorized as intermediate K-MRD⁺ or good K-MRD⁺. Survival outcomes of these subsets and those of recognized unfavorable categories, such as poor-risk cytogenetics and FLT3-ITD mutation, are shown (P < .001 for all comparisons).